The UltraMind Solution (143 page)

6
. Anisman, H., and Z. Merali. 2003. Cytokines, stress and depressive illness: Brain-immune interactions.
Ann Med
35:2–11.

7
. Banks, W. A., S. A. Farr, and J. E. Morley. 2002–2003. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes.
Neuroimmunomodulation
10:319–27.

8
. Rivier, C. 1993. Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis in the rat.
Ann N Y Acad Sci
697:97–105.

9
. Carlson, S. L., et al. 1987. Alternations of monoamines in specific central autonomic nuclei following immunization in mice.
Brain Behav Immun
1:52–63.

10
. Shattock, P., and P. Whiteley. 2002. Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biomedical intervention.
Expert Opin Ther Targets
6 (2):175–83. Review.

11
. Pimentel, M., et al. 2006. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial.
Ann Intern Med
145 (8):557–63.

12
. Av, S. P. 2007. Hepatic encephalopathy: Pathophysiology and advances in therapy.
Trop Gastroenterol
28 (1):4–10. Review.

13
. Jansson-Nettelbladt, E., et al. 2006. Endogenous ethanol fermentation in a child with short bowel syndrome.
Acta Paediatr
95 (4):502–4.

14
. Kidd, P. M. 2002. Autism, an extreme challenge to integrative medicine. Part 2: Medical management.
Altern Med Rev
7 (6):472–99. Review.

15
. Sandler, R. H., et al. 2000. Short-term benefit from oral vancomycin treatment of regressive-onset autism.
J Child Neurol
15 (7):429–35.

16
. Parracho, H. M., et al. 2005. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children.
J Med Microbiol.
54 (Pt. 10):987–91.

17
. Walsh, W. J., L. B. Glab, and M. L. Haakenson. 2004. Reduced violent behavior following biochemical therapy.
Physiol Behav
82 (5):835–39.

18
. Ibid.

19
. Benton, D. 2001. The impact of diet on antisocial, violent and criminal behaviour.
Neurosci Biobehav Rev
31 (5):752–74. Epub 2007 March 4. Review.

20
. Wakefield, A. J., et al. 2002. Review article: The concept of entero-colonic encephalopathy, autism and opioid receptor ligands.
Aliment Pharmacol Ther
16 (4):663–74.

21
. Aytac, U., and N. H. Dang. 2004. CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy.
Curr Drug Targets Immune Endocr Metabol Disord
4 (1):11–8. Review.

22
. Mentlein, R. 1999. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides.
Regul Pept
85 (1):9–24. Review.

23
. Shattock, P., and P. Whiteley. 2002. Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biomedical intervention.
Expert Opin Ther Targets
6 (2):175–83.

24
. Ek, J., M. Stensrud, and K. L. Reichelt. 1999. Gluten-free diet decreases urinary peptide levels in children with celiac disease.
J Pediatr Gastroenterol Nutr
29 (3):282–85.

25
. Liu, Y., T. Heiberg, and K. L. Reichelt. 2007. Towards a possible aetiology for depressions?
Behav Brain Funct
14 3:47.

26
. Wakefield, A. I., et al. 2005. The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder.
Eur J Gastroenterol Hepatol
17 (8):827–36.

27
. Uhlmann, V., et al. 2002. Potential viral pathogenic mechanism for new variant inflammatory bowel disease.
Mol Pathol
55 (2):84–90.

28
. Kawashima, H., et al. 2002. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism.
Dig Dis Sci
45 (4):723–29.

29
. Bradstreet, J. J., et al. 2004. Detection of measles virus genomic RNA in cerebrospinal fluid of children with regressive autism: A report of three cases.
J. Am Phys Surgeons
38–45.

30
. Taylor, B., et al. 1999. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association.
Lancet
353 (9169):2026–2029.

31
. Millward, C., et al. 2004. Gluten-and casein-free diets for autistic spectrum disorder.
Cochrane Database Syst Rev
(2):CD003498. Review.

32
. Hu, W. T., et al. 2006. Cognitive impairment and celiac disease.
Arch Neurol
63 (10):1440–446.

33
. Kalaydijian, A. E., et al. 2006. The gluten connection: The association between schizophrenia and celiac disease.
Acta Psychiatr Scand
113 (2):82–90. Review.

34
.
www.gut.bmjjournals.com/cgi/content/abstract/53/10/1459
(Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial).

35
. Shaheen, N., and F. Ransohoff. 2002. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific Review.
JAMA
287: 1972–1981.

36
.
www.en.wikipedia.org/wiki/List_of_top_selling_drugs

37
. Ruscin, J. M., R. L. Page, and R. J. Valuck. 2002. Vitamin B
₁₂
deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor.
Ann Pharmacother
36 (5):812–16.

38
. Dial, S., et al. 2005. Use of gastric acid-suppressive agents and the risk of community acquired
Clostrium difficile
-Associated Disease.
JAMA
294 (23):2989–2995.

Chapter 10: Key #5: Enhance Detoxification

1
.
www.cdc.gov/nchs/fastats/lcod.htm
.

2
. Plassman, H. I., et al. 2008. Prevalence of cognitive impairment without dementia in the United States.
Ann Intern Med
148 (6):427–34.

3
. Tsai, M. S., et al. 1994. Apolipoprotein E: risk factor for Alzheimer disease.
Am J Hum Genet
. 54 (4):643–49.

4
. Godfrey, M. E., D. P. Wojcik, and C. A. Krone. 2003. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity.
J Alzheimer’s Dis
5 (3):189–95.

5
. Clarkson, T.W., L. Magos, and G. Myers. 2003. The toxicology of mercury—current exposures and clinical manifestations.
N Engl J Med
349 (18):1731–1737. Review.

6
. Wojcik, D. P., et al. 2006. Mercury toxicity presenting as chronic fatigue, memory impairment and depression: diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994–2006).
Neuro Endocrinol Lett
27 (4):415–23.

7
. Stroombergen, M. C., and R. H. Waring. 1999. Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease.
Hum Exp Toxicol
18 (3):141–45.

8
. Bernardini, S., et al. 2005. Glutathione S transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: Association study and relationship with apolipoprotein E epsilon4 allele.
Clin Chem
51 (6):944–51. Epub 2005 April 1.

9
. Spalletta, G., et al. 2007. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease.
Am J Geriatr Psychiatry
15 (10):879–87.

10
. Gundacker, C., et al. 2007. Glutathione-S-transferase polymorphism, metallothionein expression, and mercury levels among students in Austria.
Sci Total Environ
385 (1–3):37–47. Epub 2007 Aug 22.

11
. Dorszewska, J., et al. 2007. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer’s and Parkinson’s diseases.
Acta Neurobiol Exp
(Wars) 67 (2):113–29.

12
. Rodríguez, E., et al. 2006. Cholesteryl ester transfer protein (CETP) polymorphism
modifies the Alzheimer’s disease risk associated with APOE epsilon4 allele.
J Neurol
253 (2):181–85. Epub 2005 Aug 17.

13
. Mutter, J., et al. 2007. Mercury and Alzheimer’s disease.
Fortschr Neurol Psychiatr
75 (9):528–38.

14
. Torres-Alanis, O., et al., 2000. Urinary excretion of trace elements in humans after sodium 2, 3-dimercaptopropane-1-sulfonate challenge test.
J Toxicol Clin Toxicol
38 (7):697–700.

15
. www.iaomt.org/articles/category_view.asp?intReleaseID=271&catid=30

16
. Huse, D. M., et al. 2005. Burden of illness in Parkinson’s disease.
Mov Disord
20 (11):1449–1454.

17
. Tanner, C. M., et al. 1999. Parkinson disease in twins: An etiologic study.
JAMA
281 (4):341.

18
. Cummings, J. L. 2007. Understanding Parkinson Disease.
JAMA
(1999) 281:376–78.

19
. Ayala, A., et al. Mitochondrial toxins and neurodegenerative diseases.
Front Biosci
(12):986–1007. Review.

20
. Kobal Grum, D., et al. 2006. Personality traits in miners with past occupational elemental mercury exposure.
Environ Health Perspect
114 (2):290–96.

21
. Elbaz, A., C. Dufouil and A. Alpérovitch. 2007. Interaction between genes and environment in neurodegenerative diseases.
C. R. Biol
330 (4):318–28. Epub 2007 Apr 9. Review.

22
. Skaper, S. D. 2007. The brain as a target for inflammatory processes and neuroprotective strategies.
Ann N Y Acad Sci
1122:23–34.

23
. Cummings, J. L. 1999. Understanding Parkinson’s disease.
JAMA
281 (4):376–78.

24
. Schapira, A. H., and C. W. Olanow. 2004. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
JAMA
291 (3):358–64. Review.

25
. Berg, D. 2006. Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection.
J Neural Transm Suppl
(71):123–32.

26
. Menke, A., et al. 2006. Blood level below 0.48 micromal/L (10 microg/dL) and mortality among U.S. adults.
Circulation
114 (13):1388–1394.

27
. Lindh, U., et al. 2002. Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health.
Neuro Endocrinol Lett
23 (5–6):459–82.

28
. Zachi, E. C., M.A. Faria and A. Taub. 2007. Neuropsychological dysfunction related to earlier occupational exposure to mercury vapor.
Braz J Med Biol Res
Mar 40 (3):425–33.

29
. Kokayi, K., et al. 2006. Findings of and treatment for high levels of mercury and lead toxicity in ground zero rescue and recovery workers and lower Manhattan residents.
Explore
(NY) 2 (5):400–7.

30
. Ritvo, E. R., et al. 1986. Retinal pathology in autistic children—a possible biological marker for a subtype?
J Am Acad Child Psychiatry
25 (1):137.

31
. Megson, M. N. 2000. Is autism a G-alpha protein defect reversible with natural vitamin A?
Med Hypotheses
54 (6):979–83.

32
. Peixoto, N. C., et al. 2007. Metallothionein, zinc, and mercury levels in tissues of young rats exposed to zinc and subsequently to mercury.
Life Sci
81 (16):1264– 1271. Epub 2007 September 16.

33
.
http://www.autism.com/triggers/vaccine/heavymetals.pdf

34
. Holmes, A. S., M. F. Blaxill and B. E. Haley. 2003. Reduced levels of mercury in first baby haircuts of autistic children.
Int J Toxicol
22 (4):277–85.

35
. Adams, J. B., et al. 2007. Mercury, lead, and zinc in baby teeth of children with autism versus controls.
J Toxicol Environ Health A
70 (12):1046–1051.